肥胖,吸烟和酒精对勃起功能障碍的影响:黎巴嫩男性的横截面研究
Imad Ghantous1, Mohamad Tlais2, Ali Khatib3
1Urology, Saint George University Hospital, Beirut, LBN.
Cureus
|December 3, 2025
概括
勃起功能障碍 (ED) 在45岁以上的黎巴嫩男性中非常普遍. 肥胖和吸烟显著加重ED严重程度,表明需要有针对性的公共卫生干预措施.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 男人的健康 男人的健康
- 公共卫生 公共卫生
背景情况:
- 勃起功能障碍 (ED) 是一个全球性的健康问题,已知风险因素包括年龄,吸烟,肥胖和酒精.
- 关于ED患病率和风险因素的研究有限,特别是在黎巴嫩男性人口中.
研究的目的:
- 为了确定45岁及以上的黎巴嫩男性中ED的患病率和严重程度.
- 调查ED与生活方式因素之间的关联,包括吸烟,肥胖和饮酒在这个人口群体中.
主要方法:
- 在前列腺健康运动期间,招募了150名45岁以上的男性.
- 使用国际勃起功能指数 (IIEF-5) 评估ED.
- 通过问卷收集生活方式数据 (BMI,吸烟,饮酒);进行统计分析 (基平方,逻辑回归).
主要成果:
- 在参与者中观察到高达86.7%的ED患病率.
- 体重指数 (BMI) 和吸烟与ED严重程度的增加显著相关 (p < 0.01).
- 后勤回归发现BMI是严重ED最强的预测因素 (OR = 1.21,p = 0.005).
结论:
- 肥胖和吸烟是黎巴嫩男性ED进展的关键因素.
- 调查结果强调,需要针对这一群体采取重点关注体重管理和戒烟的公共卫生倡议.
- 这项研究提供了关键的本地化数据,用于制定在黎巴嫩针对ED的定制预防策略.
相关概念视频
Stress Prevention and Stress Management Techniques IV
214
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
214
Disorders of the Male Reproductive System
3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
161
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
161
Drug Dosing: Obese Patients
202
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
202
Atherosclerosis III: Management
296
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
296
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
225
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
225


